Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia 42Leukemia, Lymphocytic, Chronic, B-Cell 41Lymphoma 30Myelodysplastic Syndromes 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Non-Hodgkin 18Hodgkin Disease 18Leukemia, Myeloid, Acute 17Multiple Myeloma 16Myeloproliferative Disorders 14Lymphoma, Mantle-Cell 10Lymphoma, Follicular 10Neoplasms, Plasma Cell 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, B-Cell, Marginal Zone 9Leukemia, Myeloid, Chronic-Phase 9Congenital Abnormalities 9Lymphoma, T-Cell, Peripheral 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Hematologic Neoplasms 8Burkitt Lymphoma 8Anemia, Aplastic 8Waldenstrom Macroglobulinemia 7Recurrence 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, Large-Cell, Immunoblastic 7Primary Myelofibrosis 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 6Leukemia, Myeloid, Accelerated Phase 6

Interventions

Cyclophosphamide 10fludarabine 7Rituximab 6Bendamustine Hydrochloride 5venetoclax 4obinutuzumab 4Lenalidomide 4ofatumumab 3ibrutinib 3fludarabine phosphate 3acalabrutinib 3Vincristine 3Immunotherapy, Adoptive 3pirtobrutinib 2Bortezomib 2Alemtuzumab 2zanubrutinib 1thymoglobulin 1tenofovir alafenamide 1ricolinostat 1pembrolizumab 1pegaspargase 1nelarabine 1idelalisib 1blinatumomab 1Whole-Body Irradiation 1Prednisolone 1Pentostatin 1Panobinostat 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Leukemia, B-Cell × Alemtuzumab × Clear all
NCT00230282 2014-10-06

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Stanford University

Phase 2 Completed
25 enrolled 7 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00292760 2009-12-16

A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion

Royal Marsden NHS Foundation Trust

Phase 2 Completed
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡